These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19557028)

  • 1. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes.
    Magae J; Tsuruga M; Maruyama A; Furukawa C; Kojima S; Shimizu H; Ando K
    J Antibiot (Tokyo); 2009 Jul; 62(7):365-9. PubMed ID: 19557028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
    Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
    Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
    Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
    J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
    J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
    Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB
    J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
    Loffler M; Bilban M; Reimers M; Waldhäusl W; Stulnig TM
    J Pharmacol Exp Ther; 2006 Feb; 316(2):797-804. PubMed ID: 16260581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
    Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
    Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
    Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
    J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative image analysis in adipose tissue using an automated image analysis system: differential effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist on white and brown adipose tissue morphology in AKR obese and db/db diabetic mice.
    Okamoto Y; Higashiyama H; Inoue H; Kanematsu M; Kinoshita M; Asano S
    Pathol Int; 2007 Jun; 57(6):369-77. PubMed ID: 17539968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
    Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
    J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR-gamma: therapeutic target for ischemic stroke.
    Culman J; Zhao Y; Gohlke P; Herdegen T
    Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway.
    Hung SH; Yeh CH; Huang HT; Wu P; Ho ML; Chen CH; Wang C; Chao D; Wang GJ
    Life Sci; 2008 Mar; 82(11-12):561-9. PubMed ID: 18272184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.